To assess this, we used JAK1/2-selective inhibitor ruxolitinib to assess the sensitivity of mROS production in HSVSMCs from non-diabetic and T2DM patients in response to inhibition of the JAK/STAT pathway. The gene discussed is JAK1; the disease is type 2 diabetes mellitus.